CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 30 enrolled
Drug / intervention
Mucinex® ER 600 mgdrug
Likely dose
Mucinex® ER 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03644108
NCT03644108Phase 1Completed

A Phase I, Open-label, Single-dose, Single-Period Study to Evaluate the Pharmacokinetics of Mucinex® 600 mg Extended-Release Bi-layer Tablet in Normal Healthy Subjects.

Reckitt Benckiser Inc.·interventional·Posted Aug 23, 2018·Updated Feb 28, 2019

In Brief

A Phase 1 clinical trial evaluating Mucinex® ER 600 mg for Healthy Subjects. Completed, enrolled 30 participants.

Detailed Summary

Evaluate the Pharmacokinetics of Mucinex® 600 mg Extended-Release Bi-Layer Tablet in Normal Healthy Subjects

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 23, 2018
Enrollment StartJun 4, 2009
Primary CompletionJun 15, 2009
TodayJul 2, 2026
Enrollment to primary: 11 daysPosted 7.9 years ago

Interventions

Mucinex® ER 600 mgdrug

Single dose of Mucinex® 600 mg ER Bi-Layer tablet